Treatment of refractory psoriatic arthritis with infliximab: A 12 month observational study of 16 patients

Annals of the Rheumatic Diseases

Volumn 63, Issue 2, 2004, Pages 156-161

  Feletar, M ^b   Brockbank, J E ^b   Schentag, C T ^b   Lapp, V ^b   Gladman, D D ^a,b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFLIXIMAB; METHOTREXATE;

ABDOMINAL DISEASE; ABSCESS; ADULT; ALCOHOL CONSUMPTION; ANAMNESIS; ARTICLE; BACTERIAL ARTHRITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SCREENING; DRUG TOXICITY; DYSPNEA; EDEMA; ENZYME DEFECT; EPIDIDYMITIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GENITAL PAIN; HUMAN; HYDROCELE; INFECTION; INFLAMMATION; LABORATORY TEST; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; PERICHONDRITIS; PNEUMONIA; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RANK SUM TEST; REDUCTION; RESPIRATORY TRACT DISEASE; SCROTAL PAIN; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TESTIS EDEMA; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT WITHDRAWAL; URTICARIA;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; JOINTS; LIVER; MALE; MIDDLE AGED; PSORIASIS; SKIN; TREATMENT OUTCOME;

EID: 1242313906     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.006775     Document Type: Article

References (39)

1. Gladman DD, Rahman P. Psoriatic arthritis. In: Ruddy S, Harris ED, Sledge CB, Budd RC, Sergent JS, eds. Kelly's textbook of rheumatology, 6th ed. Philadelphia: Saunders, 2001:1071-9.
2. O'Neill TO, Silman AJ. Psoriatic arthritis: historical background and epidemiology. Baillieres Clin Rheumatol 1994;8:245-61.
3. Gladman DD. Psoriatic arthritis [review]. Rheum Dis Clin North Am 1998;24:829-44.
4. Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs 2002;62:2447-57.
5. Partsch G, Steiner G, Leeb BF, Dunky A, Broll H, Smolen JS. Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol 1997;24:518-23.
6. Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ. Patterns of cytokine production in psoriatic synovium. J Rheumatol 1998;25:1544-52.
7. Baeten D, Kruithof E, Van den Bosch F, Demetter P, Van Damme N, Cuvelier C, et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondyloarthropathy. Histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001;44:186-95.
8. Hohler T, Grossman S, Stradmann-Bellinghausen B, Kaluza W, Reuss E, de Vlam K, et al. Differential association of polymorphisms in the TNFalpha region with psoriatic arthritis but not psoriasis. Ann Rheum Dis 2002;61:213-18.
9. Al-Heresh AM, Proctor J, Jones SM, Dixey J, Cox B, Welsh K, et al. Tumour necrosis factor-alpha polymorphism and the HLA-Cw*0602 allele in psoriatic arthritis. Rheumatology (Oxford) 2002;41:525-30.
10. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-90.
11. Mease P, Kivitz A, Burch F, Siegel E, Cohen S, Burge D. Improvement in disease activity in patients with psoriatic arthritis receiving etanercept (Enbrel®): results or a phase 3 multicenter clinical trial [abstract]. Arthritis Rheum 2001;44(suppl 9):S90.
12. Antoni C, Kavanaugh A, Kirkham B, Burmester G, Weisman M, Keystone E, et al. The infliximab multinational psoriatic arthritis controlled trial (IMPACT) [abstract]. Arthritis Rheum 2002;46(suppl 9):S985.
13. Clegg DO, Reda DJ, Abdellatif ML. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies. A Department of Veterans Affairs cooperative study. Arthritis Rheum 1999;42:2325-9.
14. Ory P, Sharp JT, Salonen D, Rubenstein J, Mease PJ, Kivitz AJ, et al. Etanercept (Enbrel®) inhibits radiographic progression in patients with psoriatic arthritis [abstract]. Arthritis Rheum 2002;46(suppl 9):S442.
15. Elliott MJ, Maini RN, Feldmann M, Kaldman JR, Antoni C, Smolen JS, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-10.
16. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
17. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumour necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
18. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum 2002;47:506-12.
19. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safely of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
20. Gladman DD. Psoriatic arthritis [review]. Curr Opin Rheumatol 1990;2:577-81.
21. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
22. Husted J, Gladman DD, Long JA, Farewell VT, Cook R. Validating the SF-36 health questionnaire in patients with Psoriatic Arthritis. J Rheumatol 1997;24:511-17.
23. Husted J, Gladman DD, Farewell V, Long J. Modified HAQ in psoriatic arthritis. Clin Exp Rheumatol 1995;13:439-44.
24. Blackmore M, Gladman DD, Husted J, Long J, Farewell VT. Measuring health status in psoriatic arthritis: the Health Assessment Questionnaire and its modification. J Rheumatol 1995;22:886-93.
25. Schentag CT, Beaton M, Rahman P, Husted J, Gladman DD. Fatigue in psoriatic arthritis (PsA). J Rheumatol 1999;26:1627.
26. Rahman P, Gladman DD, Cook RJ, Zhou Y, Young G, Salonen D. Radiological assessment in psoriatic arthritis. Br J Rheumatol 1998;37:760-5.
27. Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. Rheumatol Int 2002;22:227-32.
28. Wollina U, Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereal 2002;16:127-9.
29. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol 2002;138:644-8.
30. Schopf RE, Aust H, Knop J. Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 2002;46:886-91.
31. Van den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
32. Kruithof E, Van den Bosch F, Baeten D, Herssens A, De Keyser F, Mielants H, et al. Repeated infusions of infliximab, a chimeric anti-TNF alpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002;61:207-12.
33. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active AS with infliximab: a randomized controlled multicentre trial. Lancet 2002;359:1187-93.
34. Maksymowych WP, Jhangri GS, Lambert RG, Mallon C, Buenviaje H, Pedrycz E, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29:959-64.
35. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001;28:1605-14.
36. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-anarysis. Am J Med 1991;90:711-16.
37. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002;359:579-80.
38. Ali Y, Shah S. Infliximab-induced systemic lupus erythematosus. Ann Intern Med 2002;137:625-6.
39. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002;11:753-5.